the aid library

Filter

446

Download

View PDF

Guide de Counseling VIH/SIDA

Ministère de la Santè et de la Prévention, Senegal Programme National de Lutte contre le SIDA (2001) C1

Download

View PDF

Éléments à prendre en considération lors de la mise en oeuvre et de l’ajustement des mesures de santé publique et des mesures sociales dans le cadre de l’épidémie de COVID-19
recommended

Organisation mondiale de la Santé OMS (2021) C_WHO

orientations provisoires, 14 juin 2021

Download

View PDF

Estimating the Future Number of Cases in the Ebola Epidemic — Liberia and Sierra Leone, 2014–2015

Centers for Disease Control and Prevention CDC (2014) C_CDC

Morbidity and Mortality Weekly Report Suppl. Vol.63/3

Download

View PDF

Guide de pratique clinique pour la prise en charge de la maladie à virus Ebola

Société canadienne de soins intensifs (SCSI), Association canadienne des médecins d’urgence (ACMU), Association pour la microbiologie médicale et l’infectiologie Canada (AMMI) (2014) C1

Ce qu’il faut savoir sur le nouveau coronavirus 2019

African Union; Africa CDC Centres for Disease Control and Prevention (Safeguarding Africa's Health) African Union; Africa CDC Centres for Disease Control and Prevention (Safeguarding Africa's Health) (2020) C2

Accessed: 02.04.2020

Download

View PDF

Reunion ministerielle d’urgence de l'union Africaine sur le COVID-19

African Union; Africa CDC Centres for Disease Control and Prevention (Safeguarding Africa's Health) (2020) C2

22 février 2020 Addis-Abeba, Éthiopie

External Link

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Gabon

Africa Center for Disease Control and Prevention (2023) CC

The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project has conducted a multi-year, multi-country study that provides stark insights on the under-reported depth of the antimicrobial resistance (AMR) crisis across Africa and lays out urgent policy recommendations to addr ... more

Download

View PDF

Catalogue of interventions addressing vaccine hesitancy

European Centre for Disease Prevention and Control ECDC (2017) C1

This catalogue provides tools and information resources to support EU/EEA countries in addressing the challenging issue of vaccine hesitancy. The catalogue provides examples of practices that can serve as a resource for other countries. The project was developed in the context of ECDC’s support fo ... more

Download

View PDF

Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

Centers for Disease Control and Prevention, National Center for HIVAIDS, et. al (2013) C_CDC

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Division of Tuberculosis Elimination.

Download

View PDF

Infant Feeding in Emergencies Module 2
recommended

ENN; IBFAN-GIFA, Fondation Terre des hommes, et al. ENN (2007)

for health and nutrition workers in emergency situations for training, practice and reference

Download

View PDF

Basic occupational safety and health for respiratory diseases

The Union (2021) C1

A desk guide for health facilities . It outlines a comprehensive approach to respiratory health, which health facilities can adapt and implement in resource-limited settings

Download

View PDF

Panorama de las tecnologías para el tratamiento de desechos infecciosos y punzocortantes en los centros de salud

Pan American Health Organisation PAHO (2020) C_WHO

External Link

Poorly Designed PPE a Global Problem forWomen HealthWorkers

Kuehn, B.M. (2022) C1

Download

View PDF

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download

View PDF

Apto para mujeres? Mejora del equipo de protección personal (EPP) para las mujeres trabajadoras de la salud y el cuidado

Women for Global Health WGH (2022) CC

Una de las muchas desigualdades de género en el personal sanitario y asistencial que COVID-19 ha puesto de manifiesto es la relativa al ajuste y el diseño de los equipos de protección individual (EPP). La rápida aparición y la escala de COVID-19 condujeron a la escasez de EPP en la mayoría de ... more